Discussing the impact of COVID-19 on ACC.20/WCCardio and the cardiology community throughout the country.
While many cardiologists expected to spend the upcoming weekend in Chicago, the ongoing coronavirus disease 2019 (COVID-19) outbreak has not only altered the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC), but life across the nation.
Though the impact of COVID-19 is both immense and widespread, it does nothing to dampen or attenuate the clinical impact of the hundreds of pieces of data that were set to be presented this year’s conference. With that in mind, ACC.20/WCC made the decision to go completely virtual.
Unfortunately for cardiologists and clinicians as a whole, the rapid spread and widespread impact of the pandemic has their focus shifted away leading up to this year’s meeting. In a recent ACC House Call with Deepak Bhatt, MD, executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and professor of Medicine at Harvard Medical School, we discussed topics from ACC.20/WCC—from LDL-C lowering to ticagrelor’s impact on major adverse limb events.
Before signing off from the call, Bhatt offered his take on the ongoing outbreak and offered his sympathies to his colleagues confronting the pandemic head-on in their own practices.